Nicole Karras
Pediatric Hematology-Oncology · Duarte, CANPI 1790907962
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 26.0% of the total. 2025 is the largest year on record at $661, more than ten times the $18 reported in 2019.
Across 45 payments — averaging $40.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$471
- Incyte Corporation$359
- Adaptive Biotechnologies Corporation$176
- Novartis$148
- Sobi, Inc$125
- AstraZeneca$70
- plus $465 from 13 others
Across 103 payments — averaging $1806.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$123K
- Incyte Corporation$25K
- Pharmacyclics LLC, An Abbvie Company$19K
- AstraZeneca$19K
- Novartis$717
What the payments were for
- Food & beverage$1,76697%
- Education$483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 11 | $471 |
| Incyte Corporation | 7 | $359 |
| Adaptive Biotechnologies Corporation | 1 | $176 |
| Novartis | 2 | $148 |
| Sobi, Inc | 1 | $125 |
| AstraZeneca | 3 | $70 |
| EMD Serono, Inc. | 2 | $62 |
| Genentech USA, Inc. | 2 | $58 |
| Daiichi Sankyo Inc. | 3 | $56 |
| Seagen Inc. | 3 | $52 |
| Merck | 2 | $47 |
| Karyopharm Therapeutics Inc. | 1 | $32 |
| Genmab U.S., Inc. | 1 | $28 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Bristol Myers Squibb | 1 | $25 |
| AbbVie | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,814 in reported general payments places this provider in the 60th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Duarte
- Joseph RosenthalDuarte$39K
- Lindsey MurphyDuarte$31K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
- Elysia AlvarezPalo Alto$200K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.